Search for: "Allergan Plc" Results 21 - 40 of 40
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 Nov 2016, 11:53 pm by Kevin LaCroix
  First, on November 4, plaintiffs’ lawyers filed a securities class action lawsuit in the Central District of California against Allergan plc, Allergan’s predecessor company Actavis plc, and certain of its Allergan’s directors and officers. [read post]
21 Mar 2015, 6:26 am by Lawrence B. Ebert
Actavis plc (NYSE:ACT), No. 1:14-cv-00882 (D. [read post]
16 Nov 2017, 6:17 am
Company Name Annual Director Retainer Regeneron Pharmaceuticals $2,074,085 Tesla $1,664,928 The Goldman Sachs Group $575,000 Salesforce.com $550,000 Celgene Corporation $524,871 Reynolds American $496,480 Valeant Pharmaceuticals International $475,000 Allergan PLC $450,000 Everest Re Group, Ltd. $447,030 Oracle $429,172 (more…) [read post]
19 Apr 2021, 8:01 am by Dan Bressler
” “Illinois-based AbbVie’s involvement in the case stems from its acquisition of Allergan PLC, which is facing more than 3,000 lawsuits alleging unlawful marketing and sales of prescription narcotics. [read post]
30 Sep 2019, 6:08 am by Deb Givens
Federal Trade Commission (FTC) has requested for more information from AbbVie Inc and botox maker Allergan Plc on their $63 billion deal, the companies said on Friday. [read post]
3 Jul 2018, 7:12 am by James Yang
Allergan plc (NYSE:AGN) is a global pharmaceutical company. [read post]
18 Apr 2016, 12:49 pm by Gene Quinn
The complaint also names Allergan plc, the parent company of Watson, and Endo International plc, the parent company of Endo Pharmaceuticals Inc. [read post]
4 Jan 2017, 8:26 am by Molly Crabtree
 It is well-known that the DOJ has been investigating generic drug companies for approximately two years, and as a result of the disclosure of those investigations, shareholder class action lawsuits began being filed in November 2016 against manufacturers Endo International, plc, Allergan plc and various predecessors and executives. [read post]
4 Jan 2017, 8:26 am by Molly Crabtree
  It is well-known that the DOJ has been investigating generic drug companies for approximately two years, and as a result of the disclosure of those investigations, shareholder class action lawsuits began being filed in November 2016 against manufacturers Endo International, plc, Allergan plc, and various predecessors and executives. [read post]
23 Sep 2019, 6:31 am by Deb Givens
’s $63 billion bid for troubled smaller rival Allergan Plc were among the largest deals announced this year. [read post]
10 Sep 2015, 5:47 pm by Lawrence B. Ebert
Flash forward one hundred or so years and look at the recent Pfizer case in England:From Bloomberg:Pfizer Inc. was accused by a U.K. judge of making “groundless threats” of legal action against British doctors and drugstores if they prescribed or sold a generic version of its best-selling Lyrica treatment.Judge Richard Arnold issued the rebuke as he ruled that Allergan Plc’s Actavis unit didn’t infringe Pfizer patents with its version of the drug… [read post]
9 Mar 2022, 2:06 pm by Kevin LaCroix
.: $135 million; Allergan plc: $130 million; and GCI Liberty $110 million). [read post]
4 Nov 2011, 4:09 am by John Hopkins
GlaxoSmithKline PLC has agreed to pay the US government $3 billion to settle allegations that it violated marketing practices and may have defrauded Medicaid. [read post]
15 Feb 2022, 2:20 pm by Eugene Volokh
Defendants cite to In re Allergan PLC Securities Litigation (S.D.N.Y. 2020), where the court granted a portion of a motion to seal because the subject documents contained information about an algorithm that constituted a trade secret. [read post]
Harris is Associate Vice President and Country Manager for Allergan PLC in Brazil. [read post]
30 Jul 2021, 7:01 am by Simmons Hanly Conroy
The New York State opioid trial continues against three major drugmakers, Endo International Plc., Teva Pharmaceutical Industries Ltd., and AbbVie Inc’s Allergan unit, which all stand accused of having deceptively marketed their opioid painkillers. [read post]
1 Dec 2017, 11:35 am by Nate Nead
Big pharma players such as Eli Lilly, Novo Nordisk and Allergan are committed to voluntary price restraints, while companies such as Novartis and Roche are in favor of value-based pricing. [read post]